Where PTC Therapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
PTC Therapeutics (NASDAQ:PTCT) has received mixed analyst ratings in the last quarter, with 3 bullish, 4 somewhat bullish, 8 indifferent, 2 somewhat bearish, and 1 bearish. The average 12-month price target for the company, according to 18 analysts, is $54.56, up 0.5% from the previous average of $54.29.
July 20, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
PTC Therapeutics has received mixed analyst ratings, with a slight increase in the average 12-month price target.
The mixed analyst ratings indicate uncertainty about the company's performance. However, the slight increase in the average 12-month price target suggests a mildly positive outlook. This could potentially impact the stock price, but the direction is unclear due to the mixed ratings.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100